Samples of the pre-treatment (TRIM24-MET-i) and recurrent tumor (after chemotherapy but before cabozantinib; TRIM24-MET-r) were obtained for further characterization and disease modelling (Supplementary Fig. 4a-e; Additional File 8). This evidence concerns the gene MET and neoplasm.